16:34 EST Verastem (VSTM) jumps 50% to $5.50 on FDA priority review for Avutometinib
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem price target raised to $9 from $7 at Mizuho
- Verastem announces preliminary avutometinib and sotorasib data
- Verastem Inc. Reports Increased Operating Expenses and Net Loss
- Verastem price target lowered to $14 from $20 at Alliance Global Partners
- Verastem cuts FY24 EPS view to $4.17-$4.23 from $4.25-$4.35, consensus $4.28